Rznomics

Rznomics develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma.

Its portfolio also includes RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma, RZ-003, which is in discovery stage for Alzheimer, RZ-004, a pre-clinical product for Retinitis Pigmentosa, and RZ-005, a discovery stage product to treat Rett Syndrome. Incorporated in 2017, Rznomics is headquartered in Seongnam-si, South Korea.